Daniel Hayes

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address833 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Joyce E, Tao X, Stearns V, Hayes DF, Storniolo AM, Kidwell KM, Henry NL. Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer. Breast Cancer Res Treat. 2024 Jan 10. PMID: 38198070.
      Citations:    
    2. Cani AK, Hayes DF. Breast Cancer Circulating Tumor Cells: Current Clinical Applications and Future Prospects. Clin Chem. 2024 Jan 04; 70(1):68-80. PMID: 38175590.
      Citations:    
    3. Rutherford DV, Medley S, Henderson NC, Gersch CL, Vandenberg TA, Albain KS, Dakhil SR, Tirumali NR, Gralow JR, Hortobagyi GN, Pusztai L, Mehta RS, Hayes DF, Kidwell KM, Henry NL, Barlow WE, Rae JM, Hertz DL. Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. Pharmacogenomics. 2023 Aug 24. PMID: 37615099.
      Citations:    
    4. Morikawa A, Li J, Ulintz P, Cheng X, Apfel A, Robinson D, Hopkins A, Kumar-Sinha C, Wu YM, Serhan H, Verbal K, Thomas D, Hayes DF, Chinnaiyan AM, Baladandayuthapani V, Heth J, Soellner MB, Merajver SD, Merrill N. Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment. Cancer Res Commun. 2023 06; 3(6):1093-1103. PMID: 37377606.
      Citations:    
    5. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology-College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2023 Jun 07. PMID: 37303228.
      Citations:    
    6. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023 Jun 07; JCO2202864. PMID: 37284804.
      Citations:    
    7. Plichta JK, Thomas SM, Hayes DF, Chavez-MacGregor M, Allison K, de Los Santos J, Fowler AM, Giuliano AE, Sharma P, Smith BD, van Eycken E, Edge SB, Hortobagyi GN. Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer. J Clin Oncol. 2023 Mar 21; JCO2202222. PMID: 36944149.
      Citations:    
    8. Bergqvist M, Nordmark A, Williams A, Paoletti C, Barlow W, Cobain EF, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Thymidine kinase activity levels in serum can identify HR+?metastatic breast?cancer patients with a low risk of early progression (SWOG S0226). Biomarkers. 2023 Jan 29; 1-10. PMID: 36647745.
      Citations:    
    9. Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023 Jan 17; JCO2201499. PMID: 36649570.
      Citations:    
    10. Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2023 02; 24(2):162-174. PMID: 36623515.
      Citations:    
    11. Nanou A, Miao J, Coumans FAW, Dolce EM, Darga E, Barlow W, Smerage JB, Paoletti C, Godwin AK, Pusztai L, Sharma P, Thompson A, Hortobagyi GN, Terstappen LWMM, Hayes DF. Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. JCO Precis Oncol. 2023 01; 7:e2200372. PMID: 36634296.
      Citations:    
    12. Hayes DF, Sauerbrei W, McShane LM. REMARK guidelines for tumour biomarker study reporting: a remarkable history. Br J Cancer. 2023 Feb; 128(3):443-445. PMID: 36476656.
      Citations:    
    13. Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precis Oncol. 2022 11; 6:e2200454. PMID: 36446042.
      Citations:    
    14. Dowsett M, Nielsen TO, Rimm DL, Hayes DF. Ki67 as a Companion Diagnostic: Good or Bad News? J Clin Oncol. 2022 11 20; 40(33):3796-3799. PMID: 35816627.
      Citations:    
    15. Hertz DL, Douglas JA, Miller RM, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms. Support Care Cancer. 2022 Oct; 30(10):8059-8067. PMID: 35776183.
      Citations:    
    16. Cobain EF, Hayes DF. Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2022 11 10; 40(32):3673-3676. PMID: 35767772.
      Citations:    
    17. Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai Y, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hartman J, Kos Z, L?nkholm AV, Laurinavicius A, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Mod Pathol. 2022 10; 35(10):1362-1369. PMID: 35729220.
      Citations:    
    18. Michmerhuizen AR, Lerner LM, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, Liu M, Nino C, Jungles K, Azaria R, Jelley A, Zambrana Garcia N, Harold A, Zhang A, Wharram B, Hayes DF, Rae JM, Pierce LJ, Speers CW. Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. NPJ Breast Cancer. 2022 Apr 20; 8(1):54. PMID: 35444242.
      Citations:    
    19. Hertz DL, McShane LM, Hayes DF. Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. J Clin Oncol. 2022 06 01; 40(16):1721-1731. PMID: 35324346.
      Citations:    
    20. Michmerhuizen AR, Lerner LM, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, Liu M, Nino C, Jungles K, Azaria R, Jelley A, Zambrana Garcia N, Harold A, Zhang A, Wharram B, Hayes DF, Rae JM, Pierce LJ, Speers CW. Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. NPJ Breast Cancer. 2022 Mar 10; 8(1):31. PMID: 35273179.
      Citations:    
    21. Moore HCF, Barlow WE, Somlo G, Gralow JR, Schott AF, Hayes DF, Kuhn P, Hicks JB, Welter L, Dy PA, Yeon CH, Conlin AK, Balcueva E, Lew DL, Tripathy D, Pusztai L, Hortobagyi GN. A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222. Clin Cancer Res. 2022 02 15; 28(4):611-617. PMID: 34844978.
      Citations:    
    22. Hertz DL, Chen L, Henry NL, Griggs JJ, Hayes DF, Derstine BA, Su GL, Wang SC, Pai MP. Muscle mass affects paclitaxel systemic exposure and may inform personalized paclitaxel dosing. Br J Clin Pharmacol. 2022 07; 88(7):3222-3229. PMID: 35083783.
      Citations:    
    23. Cani AK, Dolce EM, Darga EP, Hu K, Liu CJ, Pierce J, Bradbury K, Kilgour E, Aung K, Schiavon G, Carroll D, Carr TH, Klinowska T, Lindemann J, Marshall G, Rowlands V, Harrington EA, Barrett JC, Sathiyayogan N, Morrow C, Sero V, Armstrong AC, Baird R, Hamilton E, Im SA, Jhaveri K, Patel MR, Dive C, Tomlins SA, Udager AM, Hayes DF, Paoletti C. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. Mol Oncol. 2022 05; 16(10):1969-1985. PMID: 34866317.
      Citations:    
    24. Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021 12 16; 385(25):2336-2347. PMID: 34914339.
      Citations:    
    25. Darga EP, Dolce EM, Fang F, Kidwell KM, Gersch CL, Kregel S, Thomas DG, Gill A, Brown ME, Gross S, Connelly M, Holinstat M, Cobain EF, Rae JM, Hayes DF, Paoletti C. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS One. 2021; 16(11):e0260124. PMID: 34780566.
      Citations:    
    26. Nielsen TO, Leung SCY, McShane LM, Dowsett M, Hayes DF. Response to Zhang and Yang. J Natl Cancer Inst. 2021 11 02; 113(11):1597-1598. PMID: 34003287.
      Citations:    
    27. Smith KJ, Jana JA, Kaehr A, Purcell E, Opdycke T, Paoletti C, Cooling L, Thamm DH, Hayes DF, Nagrath S. Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKey? device for CTC enrichment. Lab Chip. 2021 09 14; 21(18):3559-3572. PMID: 34320046.
      Citations:    
    28. Paoletti C, Barlow WE, Cobain EF, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae JM. Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clin Cancer Res. 2021 11 15; 27(22):6115-6123. PMID: 34521624.
      Citations:    
    29. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021 07 01; 113(7):808-819. PMID: 33369635.
      Citations:    
    30. Hertz DL, Douglas JA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. Pharmacogenet Genomics. 2021 07 01; 31(5):116-123. PMID: 34096894.
      Citations:    
    31. Paoletti C, Regan MM, Niman SM, Dolce EM, Darga EP, Liu MC, Marcom PK, Hart LL, Smith JW, Tedesco KL, Amir E, Krop IE, DeMichele AM, Goodwin PJ, Block M, Aung K, Brown ME, McCormack RT, Hayes DF. Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. NPJ Breast Cancer. 2021 Jun 11; 7(1):77. PMID: 34117261.
      Citations:    
    32. Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. J Natl Cancer Inst. 2021 04 06; 113(4):390-399. PMID: 32986828.
      Citations:    
    33. Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncol. 2021 Apr 01; 7(4):525-533. PMID: 33630025.
      Citations:    
    34. Sanchez JA, Portillo S, Zarka MA, Snedden D, Pyle D, Goodman H, Hayes DF. Improving Oncology-Pathology Collaboration in Resource-Limited Settings: An American Society of Clinical Oncology/College of American Pathologists Initiative. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:199-220. PMID: 34010051.
      Citations:    
    35. Hayes DF. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. J Clin Oncol. 2021 01 20; 39(3):238-248. PMID: 33326253.
      Citations:    
    36. Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, Hertz DL, Gersch C, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral Dis. 2022 Jan; 28(1):193-201. PMID: 33274559.
      Citations:    
    37. Chen Y, Fang F, Kidwell KM, Vangipuram K, Marcath LA, Gersch CL, Rae JM, Hayes DF, Lavoie Smith EM, Henry NL, Beutler AS, Hertz DL. Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Pharmacogenomics. 2020 08; 21(12):841-851. PMID: 32700628.
      Citations:    
    38. Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020 07 01; 112(7):698-707. PMID: 31693129.
      Citations:    
    39. Wagner LI, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, Tevaarwerk AJ, Carlos RC, Albain KS, Olson JA, Goetz MP, Pritchard KI, Hayes DF, Geyer CE, Dees EC, McCaskill-Stevens WJ, Minasian LM, Sledge GW, Cella D. Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. J Clin Oncol. 2020 06 10; 38(17):1875-1886. PMID: 32271671.
      Citations:    
    40. Woodward WA, Barlow WE, Jagsi R, Buchholz TA, Shak S, Baehner F, Whelan TJ, Davidson NE, Ingle JN, King TA, Ravdin PM, Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncol. 2020 04 01; 6(4):505-511. PMID: 31917424.
      Citations:    
    41. Gonzalez TL, Hancock M, Sun S, Gersch CL, Larios JM, David W, Hu J, Hayes DF, Wang S, Rae JM. Correction to: Targeted degradation of activating estrogen receptor a ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 2020 04; 180(3):623. PMID: 32180072.
      Citations:    
    42. Jennaro TS, Fang F, Kidwell KM, Smith EML, Vangipuram K, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Henry NL, Hertz DL. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2020 Apr; 180(3):707-714. PMID: 32166478.
      Citations:    
    43. Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE, Olson JA, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. JAMA Oncol. 2020 03 01; 6(3):367-374. PMID: 31566680.
      Citations:    
    44. Gonzalez TL, Hancock M, Sun S, Gersch CL, Larios JM, David W, Hu J, Hayes DF, Wang S, Rae JM. Targeted degradation of activating estrogen receptor a ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 2020 Apr; 180(3):611-622. PMID: 32067153.
      Citations:    
    45. Marcath LA, Kidwell KM, Vangipuram K, Gersch CL, Rae JM, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Smith EML, Henry NL, Beutler AS, Hertz DL. Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Br J Clin Pharmacol. 2020 05; 86(5):880-890. PMID: 31823378.
      Citations:    
    46. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020 05; 144(5):545-563. PMID: 31928354.
      Citations:    
    47. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020 04 20; 38(12):1346-1366. PMID: 31928404.
      Citations:    
    48. Hayes DF. Progress in the Treatment of Breast Cancer. Reply. N Engl J Med. 2020 01 09; 382(2):e4. PMID: 31914254.
      Citations:    
    49. Cobain EF, Paoletti C, Smerage JB, Hayes DF. Clinical Applications of Circulating Tumor Cells in Breast Cancer. Recent Results Cancer Res. 2020; 215:147-160. PMID: 31605228.
      Citations:    
    50. Hayes DF, Rae JM. Pharmacogenomics and Endocrine Therapy in Breast Cancer. J Clin Oncol. 2020 02 20; 38(6):525-528. PMID: 31880969.
      Citations:    
    51. Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, G?kmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. J Clin Oncol. 2019 12 20; 37(36):3484-3492. PMID: 31657982.
      Citations:    
    52. Hayes DF. HER2 and Breast Cancer - A Phenomenal Success Story. N Engl J Med. 2019 09 26; 381(13):1284-1286. PMID: 31502769.
      Citations:    
    53. Dowling RJO, Kalinsky K, Hayes DF, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Thorat MA, Whelan TJ, Wolff AC, Woodgett JR, Sparano JA, Goodwin PJ. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz050. PMID: 32337479.
      Citations:    
    54. Dowling RJO, Sparano JA, Goodwin PJ, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Thorat MA, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Whelan TJ, Wolff AC, Woodgett JR, Kalinsky K, Hayes DF. Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz049. PMID: 32337478.
      Citations:    
    55. Paoletti C, Miao J, Dolce EM, Darga EP, Repollet MI, Doyle GV, Gralow JR, Hortobagyi GN, Smerage JB, Barlow WE, Hayes DF. Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. Clin Cancer Res. 2019 10 15; 25(20):6089-6097. PMID: 31358544.
      Citations:    
    56. Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology. 2019 Aug; 75(2):225-235. PMID: 31017314.
      Citations:    
    57. Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019 06 20; 380(25):2395-2405. PMID: 31157962.
      Citations:    
    58. Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL. Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. Pharmacogenomics. 2019 06; 20(8):571-580. PMID: 31190621.
      Citations:    
    59. Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. Breast Cancer Res Treat. 2019 Aug; 176(3):617-624. PMID: 31079282.
      Citations:    
    60. Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh ZA, Hayes DF, Hortobagyi GN, Barlow WE, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. J Immunother Cancer. 2019 04 10; 7(1):88. PMID: 30967156.
      Citations:    
    61. Kim TH, Wang Y, Oliver CR, Thamm DH, Cooling L, Paoletti C, Smith KJ, Nagrath S, Hayes DF. A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. Nat Commun. 2019 04 01; 10(1):1478. PMID: 30932020.
      Citations:    
    62. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN. Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. N Engl J Med. 2019 03 28; 380(13):1226-1234. PMID: 30917258.
      Citations:    
    63. Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study. Clin Breast Cancer. 2019 08; 19(4):225-235.e2. PMID: 30928413.
      Citations:    
    64. Hayes DF. Further Progress for Patients with Breast Cancer. N Engl J Med. 2019 02 14; 380(7):676-677. PMID: 30763184.
      Citations:    
    65. Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL. Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion. Breast Cancer Res Treat. 2019 Jun; 175(2):297-303. PMID: 30747308.
      Citations:    
    66. Kadakia KC, Kidwell KM, Barton DL, Schott AF, Hayes DF, Griggs JJ, Henry NL. Factors influencing the use of extended adjuvant endocrine therapy. Breast Cancer Res Treat. 2019 May; 175(1):181-189. PMID: 30706190.
      Citations:    
    67. Marcath LA, Kidwell KM, Robinson AC, Vangipuram K, Burness ML, Griggs JJ, Poznak CV, Schott AF, Hayes DF, Henry NL, Hertz DL. Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. Pharmacogenomics. 2019 01; 20(2):95-104. PMID: 30520341.
      Citations:    
    68. Rimm DL, Leung SCY, McShane LM, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere EK, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga EN, Laurinavicius A, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes DF, Nielsen TO, Dowsett M. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Mod Pathol. 2019 01; 32(1):59-69. PMID: 30143750.
      Citations:    
    69. Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF. Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. Clin Cancer Res. 2018 12 01; 24(23):5860-5872. PMID: 30082476.
      Citations:    
    70. Sun Y, Kim JH, Vangipuram K, Hayes DF, Smith EML, Yeomans L, Henry NL, Stringer KA, Hertz DL. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2018 Oct; 171(3):657-666. PMID: 29946863.
      Citations:    
    71. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):111-121. PMID: 29860917.
      Citations:    
    72. Hayes DF. Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal? JAMA Oncol. 2018 06 01; 4(6):773-774. PMID: 29242914.
      Citations:    
    73. Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. Breast Cancer Res Treat. 2018 Aug; 171(1):121-129. PMID: 29752687.
      Citations:    
    74. Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL. Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res. 2018 08 01; 24(15):3602-3610. PMID: 29703818.
      Citations:    
    75. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med. 2018 10; 142(10):1242-1253. PMID: 29504834.
      Citations:    
    76. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 06 01; 36(16):1631-1641. PMID: 29504847.
      Citations:    
    77. Pan H, Gray R, Hayes DF. Breast-Cancer Recurrence after Stopping Endocrine Therapy. N Engl J Med. 2018 03 01; 378(9):870-871. PMID: 29490180.
      Citations:    
    78. Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. J Clin Oncol. 2018 02 20; 36(6):617-623. PMID: 29236570.
      Citations:    
    79. Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, Hayes DF, Rae JM, Tomlins SA. Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. Cancer Res. 2018 02 15; 78(4):1110-1122. PMID: 29233927.
      Citations:    
    80. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017 11 09; 377(19):1836-1846. PMID: 29117498.
      Citations:    
    81. Hayes DF, Vose JM. Delivery of Personalized Medicine With Precision. JCO Precis Oncol. 2017 Nov; 1:1-3. PMID: 35172479.
      Citations:    
    82. Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng FY. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. NPJ Breast Cancer. 2017; 3:29. PMID: 28840192.
      Citations:    
    83. Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, Schuetze S, Alva A, Siddiqui J, Chugh R, Worden F, Zalupski MM, Innis J, Mody RJ, Tomlins SA, Lucas D, Baker LH, Ramnath N, Schott AF, Hayes DF, Vijai J, Offit K, Stoffel EM, Roberts JS, Smith DC, Kunju LP, Talpaz M, Cieslik M, Chinnaiyan AM. Integrative clinical genomics of metastatic cancer. Nature. 2017 08 17; 548(7667):297-303. PMID: 28783718.
      Citations:    
    84. Hayes DF. Making a Difference in Cancer Care With You. J Clin Oncol. 2017 08 20; 35(24):2723-2728. PMID: 28678666.
      Citations:    
    85. Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5687-5695. PMID: 28679771.
      Citations:    
    86. Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM. Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat. 2017 Oct; 165(3):659-668. PMID: 28643023.
      Citations:    
    87. Winkfield KM, Flowers CR, Patel JD, Rodriguez G, Robinson P, Agarwal A, Pierce L, Brawley OW, Mitchell EP, Head-Smith KT, Wollins DS, Hayes DF. American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. J Clin Oncol. 2017 Aug 01; 35(22):2576-2579. PMID: 28459634.
      Citations:    
    88. Kadakia KC, Kidwell KM, Seewald NJ, Snyder CF, Storniolo AM, Otte JL, Flockhart DA, Hayes DF, Stearns V, Henry NL. Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat. 2017 Jul; 164(2):411-419. PMID: 28451964.
      Citations:    
    89. Henry NL, Speth K, Lintermans A, Kidwell KM, Carlson R, Hayes DF, Neven P. Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation. Clin Breast Cancer. 2017 08; 17(5):350-355.e4. PMID: 28365336.
      Citations:    
    90. Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res. 2017 05 01; 77(9):2476-2487. PMID: 28209615.
      Citations:    
    91. Jung MS, Zhang M, Askren MK, Berman MG, Peltier S, Hayes DF, Therrien B, Reuter-Lorenz PA, Cimprich B. Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis. Brain Imaging Behav. 2017 02; 11(1):86-97. PMID: 26809289.
      Citations:    
    92. Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat. 2017 02; 161(3):453-461. PMID: 27943008.
      Citations:    
    93. Vose JM, Levit LA, Hurley P, Lee C, Thompson MA, Stewart T, Hofacker J, Bruinooge SS, Hayes DF. Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. J Clin Oncol. 2016 11 01; 34(31):3796-3802. PMID: 27601549.
      Citations:    
    94. Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 2016 09 26; 7:12791. PMID: 27666543.
      Citations:    
    95. Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. Physiol Genomics. 2016 09 01; 48(9):688-98. PMID: 27542969.
      Citations:    
    96. Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat. 2016 08; 159(1):87-95. PMID: 27475087.
      Citations:    
    97. Somerfield MR, Bohlke K, Browman GP, Denduluri N, Einhaus K, Hayes DF, Khorana AA, Miller RS, Mohile SG, Oliver TK, Ortiz E, Lyman GH. Innovations in American Society of Clinical Oncology Practice Guideline Development. J Clin Oncol. 2016 09 10; 34(26):3213-20. PMID: 27382097.
      Citations:    
    98. Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng FY. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. Clin Cancer Res. 2016 Dec 01; 22(23):5864-5875. PMID: 27225691.
      Citations:    
    99. Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Enos RA, Fineberg S, Focke CM, Gao D, Gown AM, Grabau D, Gutierrez C, Hugh JC, Kos Z, L?nkholm AV, Lin MG, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Viale G, Hayes DF, McShane LM, Dowsett M. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016; 2:16014. PMID: 28721378.
      Citations:    
    100. Paoletti C, Larios JM, Mu?iz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. Mol Oncol. 2016 08; 10(7):1078-85. PMID: 27178224.
      Citations:    
    101. Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, Hayes DF, Merajver SD, Rae JM, Tewari M. Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. Clin Biochem. 2016 Dec; 49(18):1354-1360. PMID: 27129799.
      Citations:    
    102. Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM. Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. Br J Clin Pharmacol. 2016 06; 81(6):1134-41. PMID: 26859101.
      Citations:    
    103. Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist. 2016 05; 21(5):539-46. PMID: 27009936.
      Citations:    
    104. Harris LN, Ismaila N, McShane LM, Hayes DF. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2016 Apr; 12(4):384-9. PMID: 26957642.
      Citations:    
    105. Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF, Henry NL. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016 Feb; 155(3):589-95. PMID: 26875184.
      Citations:    
    106. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Apr 01; 34(10):1134-50. PMID: 26858339.
      Citations:    
    107. Hayes DF. Is Breast Cancer a Curable Disease? J Oncol Pract. 2016 Jan; 12(1):13-6. PMID: 26759460.
      Citations:    
    108. Paoletti C, Hayes DF. Circulating Tumor Cells. Adv Exp Med Biol. 2016; 882:235-58. PMID: 26987538.
      Citations:    
    109. Hayes DF. Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care. Am Soc Clin Oncol Educ Book. 2016; 35:292-6. PMID: 27249708.
      Citations:    
    110. Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast Cancer Res Treat. 2015 Nov; 154(2):263-73. PMID: 26536870.
      Citations:    
    111. Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. Clin Cancer Res. 2016 Mar 15; 22(6):1395-402. PMID: 26463708.
      Citations:    
    112. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19; 373(21):2005-14. PMID: 26412349.
      Citations:    
    113. Yu PP, Vose JM, Hayes DF. Genetic Cancer Susceptibility Testing: Increased Technology, Increased Complexity. J Clin Oncol. 2015 Nov 01; 33(31):3533-4. PMID: 26324366.
      Citations:    
    114. Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons HA, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan AM, Schott A, Robinson D, Jacks KS, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH. ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clin Cancer Res. 2016 Feb 15; 22(4):993-9. PMID: 26261103.
      Citations:    
    115. Hayes DF. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. Breast. 2015 Nov; 24 Suppl 2:S6-S10. PMID: 26238437.
      Citations:    
    116. Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM. Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol. 2015 Nov; 9(9):1868-76. PMID: 26276228.
      Citations:    
    117. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015 Aug 20; 33(24):2695-704. PMID: 26195705.
      Citations:    
    118. Caram MEV, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, Hayes DF, Van Poznak C, Cooney KA, Hertz DL, Banerjee M, Griggs JJ. Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Res Treat. 2015 Jul; 152(1):163-172. PMID: 26050157.
      Citations:    
    119. Cobain EF, Hayes DF. Indications for prognostic gene expression profiling in early breast cancer. Curr Treat Options Oncol. 2015 May; 16(5):23. PMID: 25929335.
      Citations:    
    120. Hayes DF, Schott AF. Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator? J Natl Cancer Inst Monogr. 2015 May; 2015(51):36-9. PMID: 26063884.
      Citations:    
    121. Schott AF, Perou CM, Hayes DF. Genome Medicine in Cancer: What's in a Name? Cancer Res. 2015 May 15; 75(10):1930-5. PMID: 25920349.
      Citations:    
    122. Duffy MJ, Sturgeon CM, S?l?tormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM. Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem. 2015 Jun; 61(6):809-20. PMID: 25882892.
      Citations:    
    123. Smerage JB, Barlow WE, Hortobagyi GN, Hayes DF. Reply to F.-C. Bidard et al. J Clin Oncol. 2015 May 10; 33(14):1623. PMID: 25870090.
      Citations:    
    124. Paoletti C, Li Y, Mu?iz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res. 2015 Jun 15; 21(12):2771-9. PMID: 25779948.
      Citations:    
    125. Wolff AC, Hammond ME, Hicks DG, Allison KH, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Dowsett M, McShane LM, Hayes DF. Reply to E.A. Rakha et al. J Clin Oncol. 2015 Apr 10; 33(11):1302-4. PMID: 25753441.
      Citations:    
    126. Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, L?nkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO. An international study to increase concordance in Ki67 scoring. Mod Pathol. 2015 Jun; 28(6):778-86. PMID: 25698062.
      Citations:    
    127. Hayes DF, Schott AF. Personalized Medicine: Genomics Trials in Oncology. Trans Am Clin Climatol Assoc. 2015; 126:133-43. PMID: 26330667.
      Citations:    
    128. Paoletti C, Mu?iz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res. 2015 Jun 01; 21(11):2487-98. PMID: 25381338.
      Citations:    
    129. Hayes DF. Biomarker validation and testing. Mol Oncol. 2015 May; 9(5):960-6. PMID: 25458054.
      Citations:    
    130. Henry NL, Schott AF, Hayes DF. Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility. J Clin Oncol. 2014 Oct 10; 32(29):3207-9. PMID: 25199749.
      Citations:    
    131. Yu PP, Hoffman MA, Hayes DF. Biomarkers and oncology: the path forward to a learning health system. Arch Pathol Lab Med. 2015 Apr; 139(4):451-6. PMID: 25152310.
      Citations:    
    132. Askren MK, Jung M, Berman MG, Zhang M, Therrien B, Peltier S, Ossher L, Hayes DF, Reuter-Lorenz PA, Cimprich B. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Breast Cancer Res Treat. 2014 Sep; 147(2):445-55. PMID: 25138546.
      Citations:    
    133. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014 Nov 01; 32(31):3483-9. PMID: 24888818.
      Citations:    
    134. Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, Stearns V, Clauw DJ, Williams DA, Henry NL. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer. 2014 Aug 15; 120(16):2403-11. PMID: 24802413.
      Citations:    
    135. Wolff AC, Hammond ME, Hicks DG, Dowsett M, Hayes DF, McShane LM. Reply to R. Bhargava et al and K. Lambein et al. J Clin Oncol. 2014 Jun 10; 32(17):1857-9. PMID: 24778389.
      Citations:    
    136. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):542-90. PMID: 24717572.
      Citations:    
    137. Henry NL, Henry LN, Hayes DF, Ramsey SD, Hortobagyi GN, Barlow WE, Gralow JR. Promoting quality and evidence-based care in early-stage breast cancer follow-up. J Natl Cancer Inst. 2014 Apr; 106(4):dju034. PMID: 24627271.
      Citations:    
    138. Henry NL, Conlon A, Kidwell KM, Griffith K, Smerage JB, Schott AF, Hayes DF, Williams DA, Clauw DJ, Harte SE. Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer. J Pain. 2014 May; 15(5):468-75. PMID: 24462504.
      Citations:    
    139. Paoletti C, Hayes DF. Molecular testing in breast cancer. Annu Rev Med. 2014; 65:95-110. PMID: 24422569.
      Citations:    
    140. Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist. 2014 Jan; 19(1):68-74. PMID: 24319018.
      Citations:    
    141. Fitzgibbons PL, Dillon DA, Alsabeh R, Berman MA, Hayes DF, Hicks DG, Hughes KS, Nofech-Mozes S. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 2014 May; 138(5):595-601. PMID: 24236805.
      Citations:    
    142. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013 Dec 18; 105(24):1897-906. PMID: 24203987.
      Citations:    
    143. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013 Dec; 45(12):1446-51. PMID: 24185510.
      Citations:    
    144. Hayes DF. OMICS-based personalized oncology: if it is worth doing, it is worth doing well! BMC Med. 2013 Oct 17; 11:221. PMID: 24228698.
      Citations:    
    145. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014 Feb; 138(2):241-56. PMID: 24099077.
      Citations:    
    146. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 01; 31(31):3997-4013. PMID: 24101045.
      Citations:    
    147. Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C, Lin J, Ramnath N, Wicha MS, Hayes DF, Simeone DM, Nagrath S. Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol. 2013 Oct; 8(10):735-41. PMID: 24077027.
      Citations:    
    148. Hayes DF. Sitting with grandma. J Clin Oncol. 2013 Nov 01; 31(31):4022-3. PMID: 24062401.
      Citations:    
    149. Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst. 2013 Sep 04; 105(17):1332-4. PMID: 23958736.
      Citations:    
    150. Berman MG, Askren MK, Jung M, Therrien B, Peltier S, Noll DC, Zhang M, Ossher L, Hayes DF, Reuter-Lorenz PA, Cimprich B. Pretreatment worry and neurocognitive responses in women with breast cancer. Health Psychol. 2014 Mar; 33(3):222-31. PMID: 23914817.
      Citations:    
    151. Hayes DF. From genome to bedside: are we lost in translation? Breast. 2013 Aug; 22 Suppl 2:S22-6. PMID: 24074786.
      Citations:    
    152. Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR. Breaking a vicious cycle. Sci Transl Med. 2013 Jul 31; 5(196):196cm6. PMID: 23903752.
      Citations:    
    153. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Jul; 11(7):753-60; quiz 761. PMID: 23847214.
      Citations:    
    154. Rae JM, Regan M, Leyland-Jones B, Hayes DF, Dowsett M. CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. J Clin Oncol. 2013 Jul 20; 31(21):2753-5. PMID: 23775974.
      Citations:    
    155. Neven P, Joensuu H, Joenssu H, Osborne K, Cardoso F, Loibl S, Linn S, Goldhirsch A, Ortmann O, Senn HJ, Hayes DF. Tamoxifen therapy for patients with breast cancer. Lancet. 2013 Jun 15; 381(9883):2078. PMID: 23769226.
      Citations:    
    156. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabi?res C, Janni W, Messina C, Paoletti C, M?ller V, Hayes DF, Piccart M, Pierga JY. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013 Jun; 32(1-2):179-88. PMID: 23129208.
      Citations:    
    157. Henry NL, Skaar TC, Dantzer J, Li L, Kidwell K, Gersch C, Nguyen AT, Rae JM, Desta Z, Oesterreich S, Philips S, Carpenter JS, Storniolo AM, Stearns V, Hayes DF, Flockhart DA. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(3):807-16. PMID: 23546553.
      Citations:    
    158. Smerage JB, Budd GT, Doyle GV, Brown M, Paoletti C, Muniz M, Miller MC, Repollet MI, Chianese DA, Connelly MC, Terstappen LW, Hayes DF. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol. 2013 Jun; 7(3):680-92. PMID: 23538216.
      Citations:    
    159. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013 Mar 01; 73(5):1635-46. PMID: 23442322.
      Citations:    
    160. Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res. 2013 Mar 15; 19(6):1512-24. PMID: 23340294.
      Citations:    
    161. Jochelson M, Hayes DF, Ganz PA. Surveillance and monitoring in breast cancer survivors: maximizing benefit and minimizing harm. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714444.
      Citations:    
    162. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2013 Jan 10; 31(2):195-202. PMID: 23233719.
      Citations:    
    163. McShane LM, Hayes DF. Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol. 2012 Dec 01; 30(34):4223-32. PMID: 23071235.
      Citations:    
    164. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012 Aug 02; 367(5):435-44. PMID: 22853014.
      Citations:    
    165. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10:138. PMID: 22747748.
      Citations:    
    166. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):821-9. PMID: 22773798.
      Citations:    
    167. Wolff AC, Hammond ME, Hayes DF. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2012 Jun 20; 104(12):957-8. PMID: 22581974.
      Citations:    
    168. Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 May 20; 30(15):1747-9. PMID: 22508810.
      Citations:    
    169. Philips S, Rae JM, Oesterreich S, Hayes DF, Stearns V, Henry NL, Storniolo AM, Flockhart DA, Skaar TC. Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes. Front Pharmacol. 2012; 3:54. PMID: 22479249.
      Citations:    
    170. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012 Mar 21; 104(6):452-60. PMID: 22395643.
      Citations:    
    171. Hayes DF. Targeting adjuvant chemotherapy: a good idea that needs to be proven! J Clin Oncol. 2012 Apr 20; 30(12):1264-7. PMID: 22355050.
      Citations:    
    172. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):936-42. PMID: 22331951.
      Citations:    
    173. Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes DF, Decker DA. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012 May; 8(3):144-8. PMID: 22942807.
      Citations:    
    174. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012 Apr; 6(2):140-6. PMID: 22356776.
      Citations:    
    175. Northouse LL, Mood DW, Schafenacker A, Kalemkerian G, Zalupski M, LoRusso P, Hayes DF, Hussain M, Ruckdeschel J, Fendrick AM, Trask PC, Ronis DL, Kershaw T. Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers. Psychooncology. 2013 Mar; 22(3):555-63. PMID: 22290823.
      Citations:    
    176. Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist. 2012; 17(2):179-87. PMID: 22267853.
      Citations:    
    177. Bell LN, Nguyen AT, Li L, Desta Z, Henry NL, Hayes DF, Wolff AC, Stearns V, Storniolo AM, Flockhart DA. Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. J Clin Pharmacol. 2012 Dec; 52(12):1852-60. PMID: 22174434.
      Citations:    
    178. Bardia A, Arieas ET, Zhang Z, Defilippis A, Tarpinian K, Jeter S, Nguyen A, Henry NL, Flockhart DA, Hayes DF, Hayden J, Storniolo AM, Armstrong DK, Davidson NE, Fetting J, Ouyang P, Wolff AC, Blumenthal RS, Ashen MD, Stearns V. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2012 Feb; 131(3):907-14. PMID: 22042368.
      Citations:    
    179. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011 Nov; 9 Suppl 5:S1-32; quiz S33. PMID: 22138009.
      Citations:    
    180. Hayes DF. Disease related indicators for a proper choice of adjuvant treatments. Breast. 2011 Oct; 20 Suppl 3:S162-4. PMID: 22015287.
      Citations:    
    181. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011 Nov 16; 103(22):1656-64. PMID: 21960707.
      Citations:    
    182. Griggs JJ, Hayes DF. Do all patients with breast cancer require systemic adjuvant therapy? J Natl Cancer Inst. 2011 Sep 21; 103(18):1350-1. PMID: 21881041.
      Citations:    
    183. Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat. 2011 Dec; 130(3):993-1002. PMID: 21766209.
      Citations:    
    184. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield E, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J. Biospecimen reporting for improved study quality (BRISQ). J Proteome Res. 2011 Aug 05; 10(8):3429-38. PMID: 21574648.
      Citations:    
    185. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8. PMID: 21693655.
      Citations:    
    186. Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. 2011 Dec 15; 117(24):5469-75. PMID: 21692065.
      Citations:    
    187. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011 May 20; 29(15):e458. PMID: 21502545.
      Citations:    
    188. Moore HM, Kelly A, Jewell SD, McShane LM, Clark DP, Greenspan R, Hainaut P, Hayes DF, Kim P, Mansfield E, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J. Biospecimen Reporting for Improved Study Quality. Biopreserv Biobank. 2011 Apr; 9(1):57-70. PMID: 21826252.
      Citations:    
    189. Fagerlin A, Dillard AJ, Smith DM, Zikmund-Fisher BJ, Pitsch R, McClure JB, Greene S, Alford SH, Nair V, Hayes DF, Wiese C, Ubel PA. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011 Jun; 127(3):681-8. PMID: 21442198.
      Citations:    
    190. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 2011 Apr 25; 119(2):92-101. PMID: 21433001.
      Citations:    
    191. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol. 2011 Apr 20; 29(12):1508-11. PMID: 21422428.
      Citations:    
    192. Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes DF, Pusztai L. Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol. 2011 Mar; 8(3):171-6. PMID: 21364690.
      Citations:    
    193. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive breast cancer. J Natl Compr Canc Netw. 2011 Feb; 9(2):136-222. PMID: 21310842.
      Citations:    
    194. Djuric Z, Ellsworth JS, Weldon AL, Ren J, Richardson CR, Resnicow K, Newman LA, Hayes DF, Sen A. A Diet and Exercise Intervention during Chemotherapy for Breast Cancer. Open Obes J. 2011; 3:87-97. PMID: 22238561.
      Citations:    
    195. Hayes DF. Contribution of biomarkers to personalized medicine. Breast Cancer Res. 2010 Dec 20; 12 Suppl 4:S3. PMID: 21172087.
      Citations:    
    196. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010 Dec 15; 16(24):6169-76. PMID: 21169260.
      Citations:    
    197. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207. PMID: 20971842.
      Citations:    
    198. Henry NL, Jacobson JA, Banerjee M, Hayden J, Smerage JB, Van Poznak C, Storniolo AM, Stearns V, Hayes DF. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer. 2010 Sep 15; 116(18):4360-7. PMID: 20549827.
      Citations:    
    199. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul; 134(7):e48-72. PMID: 20586616.
      Citations:    
    200. Gilligan TD, Hayes DF, Seidenfeld J, Temin S. ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. J Oncol Pract. 2010 Jul; 6(4):199-202. PMID: 21037873.
      Citations:    
    201. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010 Jul; 6(4):195-7. PMID: 21037871.
      Citations:    
    202. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, Stephenson AJ, Vaughn DJ, Cosby R, Hayes DF. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010 Jul 10; 28(20):3388-404. PMID: 20530278.
      Citations:    
    203. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 Jun; 134(6):907-22. PMID: 20524868.
      Citations:    
    204. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 01; 28(16):2784-95. PMID: 20404251.
      Citations:    
    205. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9. PMID: 20309628.
      Citations:    
    206. Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol. 2010 Apr; 176(4):1639-47. PMID: 20150438.
      Citations:    
    207. Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, Hensley Alford S, Lantz P, Hayes DF, Wiese C, Claud Zweig S, Pitsch R, Jankovic A, Ubel PA. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat. 2010 Feb; 119(3):613-20. PMID: 19908143.
      Citations:    
    208. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010 Apr 01; 28(10):1671-6. PMID: 20065191.
      Citations:    
    209. Hayes DF, Smerage JB. Circulating tumor cells. Prog Mol Biol Transl Sci. 2010; 95:95-112. PMID: 21075330.
      Citations:    
    210. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65. PMID: 20005174.
      Citations:    
    211. Henry NL, Hayes DF, Rae JM. CYP2D6 testing for breast cancer patients: is there more to the story? Oncology (Williston Park). 2009 Dec; 23(14):1236, 1243, 1249. PMID: 20120836.
      Citations:    
    212. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009 Nov 04; 101(21):1446-52. PMID: 19815849.
      Citations:    
    213. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009 Oct; 133(10):1515-38. PMID: 19792042.
      Citations:    
    214. Hayes DF. Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer? Breast. 2009 Oct; 18 Suppl 3:S131-4. PMID: 19914531.
      Citations:    
    215. Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, Albain KS. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009 Oct 20; 27(30):4973-9. PMID: 19752340.
      Citations:    
    216. Hammond EH, Wolff AC, Hayes DF, Schwartz JN. Reply to G. Sauter et al. J Clin Oncol. 2009 Oct 20; 27(30):e153-4; author reply e155-7. PMID: 19738107.
      Citations:    
    217. Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, Hayes DF, Hooks J, Ling C, Meyskens FL, Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR, Vikram B, Zelefsky MJ, Baker LH. Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008. Clin Cancer Res. 2009 Sep 15; 15(18):5663-70. PMID: 19723641.
      Citations:    
    218. Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin. 2009 Sep-Oct; 59(5):290-302. PMID: 19679690.
      Citations:    
    219. Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66. PMID: 19671875.
      Citations:    
    220. Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, Hayes DF, Noll DC, Peltier S, Welsh RC. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010 Mar; 32(3):324-31. PMID: 19642048.
      Citations:    
    221. Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol. 2009 Aug 20; 27(24):3881-6. PMID: 19620488.
      Citations:    
    222. Hayes DF, Cristofanilli M. Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009 Jun 16; 101(12):894-5; author reply 896-7. PMID: 19509356.
      Citations:    
    223. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009 Jun 23; 106(25):10284-9. PMID: 19487683.
      Citations:    
    224. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20; 27(21):3430-6. PMID: 19470942.
      Citations:    
    225. Lippman ME, Ethier S, Hayes DF. Editorial: Cost-effective analyses in Breast Cancer Research and Treatment [corrected]. Breast Cancer Res Treat. 2009 May; 115(2):221-2. PMID: 19449205.
      Citations:    
    226. Hayes DF. Cyclin E as a prognostic factor: what is the question? Cell Cycle. 2009 Apr 01; 8(7):965. PMID: 19305167.
      Citations:    
    227. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27(12):2091-6. PMID: 19188670.
      Citations:    
    228. Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Netw. 2009 Feb; 7(2):203-13. PMID: 19200418.
      Citations:    
    229. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92. PMID: 19200416.
      Citations:    
    230. Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat. 2009 Oct; 117(3):571-5. PMID: 19153830.
      Citations:    
    231. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009 Jan; 133(1):15-25. PMID: 19123730.
      Citations:    
    232. Hayes DF. Markers of endocrine sensitivity. Breast Cancer Res. 2008; 10 Suppl 4:S18. PMID: 19128431.
      Citations:    
    233. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Br?nner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, S?l?tormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec; 54(12):e11-79. PMID: 19042984.
      Citations:    
    234. Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow J, Hortobagyi GN, Livingston R. A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. Clin Breast Cancer. 2008 Dec; 8(6):511-5. PMID: 19073506.
      Citations:    
    235. Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S, Nguyen A, Schott A, Hayden J, Lemler S, Storniolo AM, Flockhart DA, Stearns V. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol. 2008 Dec 20; 26(36):5849-54. PMID: 19018086.
      Citations:    
    236. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry. 2008 Oct; 165(10):1251-5. PMID: 18829880.
      Citations:    
    237. Kilbride KE, Lee MC, Nees AV, Cimmino VM, Diehl KM, Sabel MS, Hayes DF, Schott AF, Kleer CG, Chang AE, Newman LA. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol. 2008 Nov; 15(11):3252-8. PMID: 18784961.
      Citations:    
    238. Contreras-Galindo R, Kaplan MH, Leissner P, Verjat T, Ferlenghi I, Bagnoli F, Giusti F, Dosik MH, Hayes DF, Gitlin SD, Markovitz DM. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol. 2008 Oct; 82(19):9329-36. PMID: 18632860.
      Citations:    
    239. Eliane JP, Repollet M, Luker KE, Brown M, Rae JM, Dontu G, Schott AF, Wicha M, Doyle GV, Hayes DF, Luker GD. Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. Cancer Res. 2008 Jul 15; 68(14):5529-32. PMID: 18632603.
      Citations:    
    240. Hayes DF, Smerage J. Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res. 2008 Jun 15; 14(12):3646-50. PMID: 18559576.
      Citations:    
    241. Hayes DF, Stearns V, Rae J, Flockhart D. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst. 2008 May 07; 100(9):610-3. PMID: 18445818.
      Citations:    
    242. Sargent DJ, Hayes DF. Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol. 2008 Apr 20; 26(12):1922-3. PMID: 18421044.
      Citations:    
    243. Gonzalez RM, Seurynck-Servoss SL, Crowley SA, Brown M, Omenn GS, Hayes DF, Zangar RC. Development and validation of sandwich ELISA microarrays with minimal assay interference. J Proteome Res. 2008 Jun; 7(6):2406-14. PMID: 18422355.
      Citations:    
    244. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72. PMID: 18390970.
      Citations:    
    245. Smerage JB, Hayes DF. The prognostic implications of circulating tumor cells in patients with breast cancer. Cancer Invest. 2008 Mar; 26(2):109-14. PMID: 18259939.
      Citations:    
    246. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30. PMID: 18234424.
      Citations:    
    247. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20; 25(33):5287-312. PMID: 17954709.
      Citations:    
    248. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506. PMID: 17928597.
      Citations:    
    249. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008 Sep; 111(2):365-72. PMID: 17922185.
      Citations:    
    250. Henry NL, Hayes DF. Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer. Oncology (Williston Park). 2007 Oct; 21(11):1301-9; discussion 1311, 1314, 1319. PMID: 18080616.
      Citations:    
    251. Hayes DF, Miller K, Sledge G. Angiogenesis as targeted breast cancer therapy. Breast. 2007 Dec; 16 Suppl 2:S17-9. PMID: 17707641.
      Citations:    
    252. Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, Diehl KM, Newman LA, Sabel MS, Hayman JA, Pierce LJ, Hayes DF, Schott AF. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res. 2007 Jul 15; 13(14):4092-7. PMID: 17634534.
      Citations:    
    253. Henry NL, Hayes DF. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy? J Clin Oncol. 2007 Jun 20; 25(18):2501-3. PMID: 17577024.
      Citations:    
    254. Hayes DF. Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med. 2007 Jun 14; 356(24):2505-13. PMID: 17568031.
      Citations:    
    255. Newman EA, Sabel MS, Nees AV, Schott A, Diehl KM, Cimmino VM, Chang AE, Kleer C, Hayes DF, Newman LA. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 2007 Oct; 14(10):2946-52. PMID: 17514407.
      Citations:    
    256. Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312. PMID: 17439758.
      Citations:    
    257. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007; 131(1):18-43. PMID: 19548375.
      Citations:    
    258. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res. 2007; 9(6):R81. PMID: 18034879.
      Citations:    
    259. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 01; 25(1):118-45. PMID: 17159189.
      Citations:    
    260. Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst. 2006 Dec 06; 98(23):1723-31. PMID: 17148774.
      Citations:    
    261. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006 Nov 1; 12(21):6403-9. PMID: 17085652.
      Citations:    
    262. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006 Nov 20; 24(33):5313-27. PMID: 17060676.
      Citations:    
    263. Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer. 2006 11; 6(11):886-93. PMID: 17036039.
      Citations:    
    264. Van Poznak CH, Hayes DF. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only? J Natl Cancer Inst. 2006 Sep 20; 98(18):1261-3. PMID: 16985239.
      Citations:    
    265. Hayes DF, Picard MH. Heart of darkness: the downside of trastuzumab. J Clin Oncol. 2006 Sep 01; 24(25):4056-8. PMID: 16908930.
      Citations:    
    266. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4218-24. PMID: 16857794.
      Citations:    
    267. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006 Jul; 80(1):61-74. PMID: 16815318.
      Citations:    
    268. Hayes DF, Ethier S, Lippman ME. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat. 2006 Nov; 100(2):237-8. PMID: 16773436.
      Citations:    
    269. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006 Jun; 11(6):541-52. PMID: 16794234.
      Citations:    
    270. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8(6):R66. PMID: 17129383.
      Citations:    
    271. Henry NL, Diehl KM, Hayes DF. Adjuvant systemic therapy for elderly women with breast cancer. Womens Health (Lond). 2006 Jan; 2(1):75-87. PMID: 19803929.
      Citations:    
    272. M?ller V, Hayes DF, Pantel K. Recent translational research: circulating tumor cells in breast cancer patients. Breast Cancer Res. 2006; 8(5):110. PMID: 16953898.
      Citations:    
    273. Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V, Baker LH. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol. 2006 Jul; 58(1):129-35. PMID: 16283312.
      Citations:    
    274. Hayes DF. Prognostic and predictive factors revisited. Breast. 2005 Dec; 14(6):493-9. PMID: 16239111.
      Citations:    
    275. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, Ullmer L, Gallagher A, Cullen J, Gehan E, Hayes DF, Isaacs C. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005 Oct 01; 23(28):6919-30. PMID: 16192581.
      Citations:    
    276. Isaacs C, Slack R, Gehan E, Ballen K, Boccia R, Areman E, Kramer R, Hayes DF, Herscowitz H, Lippman M. A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients. Breast Cancer Res Treat. 2005 Sep; 93(2):125-34. PMID: 16187232.
      Citations:    
    277. Khan A, Sabel MS, Nees A, Diehl KM, Cimmino VM, Kleer CG, Schott AF, Hayes DF, Chang AE, Newman LA. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol. 2005 Sep; 12(9):697-704. PMID: 16079956.
      Citations:    
    278. Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA, Paramagul C, Baker LH. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005 Aug; 92(3):231-8. PMID: 16155794.
      Citations:    
    279. Rae JM, Goetz MP, Hayes DF, Ingle JN, Li L, Storniolo AM, Stearns V, Flockhart DA. CYP2D6 genotype and tamoxifen response. Breast Cancer Res. 2005 Jul 29; 7(5):E6. PMID: 16168100.
      Citations:    
    280. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005 Jul 01; 23(19):4287-97. PMID: 15994142.
      Citations:    
    281. Carlson RW, Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC. Breast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89. PMID: 16002000.
      Citations:    
    282. van't Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol. 2005 Mar 10; 23(8):1631-5. PMID: 15755970.
      Citations:    
    283. Hayes DF. Prognostic and predictive factors for breast cancer: translating technology to oncology. J Clin Oncol. 2005 Mar 10; 23(8):1596-7. PMID: 15755959.
      Citations:    
    284. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005 Mar 1; 23(7):1420-30. PMID: 15735118.
      Citations:    
    285. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 Jan 05; 97(1):30-9. PMID: 15632378.
      Citations:    
    286. Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R, Brown M, Cullen J, Trock B, Hayes DF. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. Clin Cancer Res. 2004 Dec 15; 10(24):8332-40. PMID: 15623610.
      Citations:    
    287. Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res. 2004 Nov 15; 10(22):7583-91. PMID: 15569989.
      Citations:    
    288. Schott A, Hayes DF. Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem. J Clin Oncol. 2004 Dec 01; 22(23):4660-2. PMID: 15505274.
      Citations:    
    289. Chen SL, Clark S, Pierce LJ, Hayes DF, Helvie MA, Greeno PL, Newman LA, Chang AE. An academic health center cost analysis of screening mammography: creating a financially viable service. Cancer. 2004 Sep 01; 101(5):1043-50. PMID: 15329914.
      Citations:    
    290. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19; 351(8):781-91. PMID: 15317891.
      Citations:    
    291. Hayes DF. Tamoxifen: Dr. Jekyll and Mr. Hyde? J Natl Cancer Inst. 2004 Jun 16; 96(12):895-7. PMID: 15199102.
      Citations:    
    292. Singer EA, Warren RD, Pennanen MF, Collins BT, Hayes DF. Tamoxifen-induced radiation recall dermatitis. Breast J. 2004 Mar-Apr; 10(2):170-1. PMID: 15009054.
      Citations:    
    293. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003 Dec 03; 95(23):1758-64. PMID: 14652237.
      Citations:    
    294. Degnim AC, Griffith KA, Sabel MS, Hayes DF, Cimmino VM, Diehl KM, Lucas PC, Snyder ML, Chang AE, Newman LA. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003 Dec 01; 98(11):2307-15. PMID: 14635063.
      Citations:    
    295. Hayes DF. Markers of increased risk for failure of adjuvant therapies. Breast. 2003 Dec; 12(6):543-9. PMID: 14659133.
      Citations:    
    296. Hayes DF. Playing the old piano: another tune for endocrine therapy? J Natl Cancer Inst. 2003 Nov 05; 95(21):1565-7. PMID: 14600082.
      Citations:    
    297. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11606-11. PMID: 14500907.
      Citations:    
    298. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003 Aug; 83(4):803-19. PMID: 12875597.
      Citations:    
    299. Sabel MS, Schott AF, Kleer CG, Merajver S, Cimmino VM, Diehl KM, Hayes DF, Chang AE, Pierce LJ. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg. 2003 Aug; 186(2):102-5. PMID: 12885598.
      Citations:    
    300. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8. PMID: 12860943.
      Citations:    
    301. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. PMID: 12637460.
      Citations:    
    302. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. PMID: 12637463.
      Citations:    
    303. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol. 2003 Feb 01; 21(3):490-5. PMID: 12560440.
      Citations:    
    304. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res. 2003 Jan; 9(1):124-33. PMID: 12538460.
      Citations:    
    305. Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell CG, Singh B, Miller WR, Stearns V, Pennanen M, Tsangaris T, Gallagher A, Liu A, Zwart A, Hayes DF, Lippman ME, Wang Y, Clarke R. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res. 2002 May; 8(5):1155-66. PMID: 12006532.
      Citations:    
    306. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002 Apr; 9(3):235-42. PMID: 11923129.
      Citations:    
    307. Stearns V, Hayes DF. Cooling off hot flashes. J Clin Oncol. 2002 Mar 15; 20(6):1436-8. PMID: 11896087.
      Citations:    
    308. Siziopikou KP, Schnitt SJ, Connolly JL, Hayes DF. Detection and Significance of Occult Axillary Metastatic Disease in Breast Cancer Patients. Breast J. 1999 Jul; 5(4):221-229. PMID: 11348291.
      Citations:    
    Hayes's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (656)
    Explore
    _
    Co-Authors (6)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _